A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours

BACKGROUND: TB-403 (RO 5323441), a humanised monoclonal antibody, is a novel antiangiogenesis agent directed against placental growth factor. The safety, pharmacokinetics (PK), and antitumour activity of TB-403 were assessed in a phase I, dose-escalation study in patients with advanced solid tumours...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassen, U, Nielsen, D L, Sørensen, M, Winstedt, L, Niskanen, T, Stenberg, Y, Pakola, S, Stassen, J-M, Glazer, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322959/
https://www.ncbi.nlm.nih.gov/pubmed/22333707
http://dx.doi.org/10.1038/bjc.2011.609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322959/
https://www.ncbi.nlm.nih.gov/pubmed/22333707
http://dx.doi.org/10.1038/bjc.2011.609

Ejemplares similares